Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zi-Wen Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 21000…. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Pyrazoles, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Natural Science Research of Jiangsu Higher Education Institutions of China, State Key Laboratory of Natural Medicines, National Natural Science Foundation of China.
Abstract (Originalsprache)
Targeting Hsp90 is an effective strategy for cancer therapy. TAS-116 has been approved for the treatment of gastrointestinal stromal tumors. Our previous studies identified a series of pyrazole derivatives as covalent Hsp90 inhibitors that allosterically disrupt the Hsp90-Cdc37 interaction. Here, through systematic structure-activity relationship (SAR) optimization, compound 39 (DDO-6691) with a new covalent warhead was developed, which demonstrates improved ADME properties and significantly enhanced antitumor activity. Notably, parental HCT-116 cells exhibited markedly greater sensitivity to compound 39 (IC50 > 50 μM) compared to their Cdc37-knockout counterparts. Importantly, compound 39 displayed potent tumor growth inhibition in HCT-116 xenograft mouse models. These collective findings underscore the therapeutic promise of covalent Hsp90-targeted disruption of the Hsp90-Cdc37 complex, offering a novel mechanistic approach to cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- School of Pharmacy, Jiangsu Health Vocational College, Nanjing 210029, China.
- Department of Pharmaceutical Analysis, College of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Qiu-Ling Zheng, Qi-Dong You, Xiao-Ke Guo, Xiao-Li Xu
Förderung
- Natural Science Research of Jiangsu Higher Education Institutions of China
- State Key Laboratory of Natural Medicines
- National Natural Science Foundation of China
- Outstanding Youth Foundation of Jiangsu Province
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Jiangsu Health Vocational College research project
Zitieren
APA
Feng, Z. W., Li, L., Zhang, S. D., Wang, Y. J., Pei, J. Y., Chen, N. N., Wu, B. D., Zheng, Q. L., You, Q. D., Guo, X. K., & Xu, X. L. (2025). Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02182
Vancouver
Feng ZW, Li L, Zhang SD, Wang YJ, Pei JY, Chen NN, et al. Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02182
BibTeX
@article{Feng2025,
author = {Feng, Zi-Wen and Li, Li and Zhang, Shi-Duo and Wang, Ying-Ji and Pei, Jia-Yue and Chen, Nan-Nan and Wu, Bei-Duo and Zheng, Qiu-Ling and You, Qi-Dong and Guo, Xiao-Ke and Xu, Xiao-Li},
title = {Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02182}
}
EUVIMED